A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
第3相
完了
NCT06041217
| 対象疾患 | Overweight, Obesity |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Novo Nordisk A/S |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 242 名 |
|---|
| 介入（薬剤） | Semaglutide |
|---|
| 開始日 | 2023年9月15日 |
|---|
| 完了日 | 2025年4月2日 |
|---|
| 結果公開日 | 2026年5月18日 |
|---|
概要
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.
Change in Body Weight (%)
Baseline (week 0), end of treatment (week 44) · Percentage change in body weight
| Semaglutide 2.4 mg | -12.2 ± 8.2 Percentage change in body weight |
|---|
| Placebo | -2.2 ± 5.4 Percentage change in body weight |
|---|
| p-value | <0.0001 |
|---|
| Treatment difference | -9.87 (95% CI -11.78–-7.96) |
|---|
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)
At end of treatment (week 44) · Participants
| Semaglutide 2.4 mg | 128 Participants |
|---|
| Placebo | 19 Participants |
|---|
| Semaglutide 2.4 mg | 31 Participants |
|---|
| Placebo | 59 Participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 14.83 (95% CI 7.42–29.63) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。